vs
Kimball Electronics, Inc.（KE）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是Kimball Electronics, Inc.的1.8倍（$622.0M vs $341.3M），Royalty Pharma plc净利率更高（34.4% vs 1.1%，领先33.4%），Royalty Pharma plc同比增速更快（4.8% vs -4.5%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -10.4%）
金伯尔国际是一家美国企业，旗下拥有金伯尔、国民、Interwoven等多个家具品牌，业务涵盖酒店家具等多元产品线。它的前身是19至20世纪一度成为全球最大钢琴与管风琴制造商的W.W.金伯尔公司，如今转型聚焦商用家具领域发展。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
KE vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.8倍
$341.3M
营收增速更快
RPRX
高出9.3%
-4.5%
净利率更高
RPRX
高出33.4%
1.1%
两年增速更快
RPRX
近两年复合增速
-10.4%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $341.3M | $622.0M |
| 净利润 | $3.6M | $214.2M |
| 毛利率 | 8.2% | — |
| 营业利润率 | 3.2% | 62.4% |
| 净利率 | 1.1% | 34.4% |
| 营收同比 | -4.5% | 4.8% |
| 净利润同比 | 6.0% | 2.9% |
| 每股收益（稀释后） | $0.15 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KERPRX
| Q4 25 | $341.3M | $622.0M | ||
| Q3 25 | $365.6M | $609.3M | ||
| Q2 25 | $380.5M | $578.7M | ||
| Q1 25 | $374.6M | $568.2M | ||
| Q4 24 | $357.4M | $593.6M | ||
| Q3 24 | $374.3M | $564.7M | ||
| Q2 24 | $430.2M | $537.3M | ||
| Q1 24 | $425.0M | $568.0M |
净利润KERPRX
| Q4 25 | $3.6M | $214.2M | ||
| Q3 25 | $10.1M | $288.2M | ||
| Q2 25 | $6.6M | $30.2M | ||
| Q1 25 | $3.8M | $238.3M | ||
| Q4 24 | $3.4M | $208.2M | ||
| Q3 24 | $3.2M | $544.0M | ||
| Q2 24 | $7.5M | $102.0M | ||
| Q1 24 | $-6.1M | $4.8M |
毛利率KERPRX
| Q4 25 | 8.2% | — | ||
| Q3 25 | 7.9% | — | ||
| Q2 25 | 8.0% | — | ||
| Q1 25 | 7.2% | — | ||
| Q4 24 | 6.6% | — | ||
| Q3 24 | 6.3% | — | ||
| Q2 24 | 8.5% | — | ||
| Q1 24 | 7.9% | — |
营业利润率KERPRX
| Q4 25 | 3.2% | 62.4% | ||
| Q3 25 | 4.0% | 70.1% | ||
| Q2 25 | 4.3% | 36.3% | ||
| Q1 25 | 3.1% | 94.0% | ||
| Q4 24 | 2.3% | 60.9% | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 4.6% | 50.2% | ||
| Q1 24 | -1.5% | -13.0% |
净利率KERPRX
| Q4 25 | 1.1% | 34.4% | ||
| Q3 25 | 2.8% | 47.3% | ||
| Q2 25 | 1.7% | 5.2% | ||
| Q1 25 | 1.0% | 41.9% | ||
| Q4 24 | 1.0% | 35.1% | ||
| Q3 24 | 0.8% | 96.3% | ||
| Q2 24 | 1.8% | 19.0% | ||
| Q1 24 | -1.4% | 0.8% |
每股收益（稀释后）KERPRX
| Q4 25 | $0.15 | $0.49 | ||
| Q3 25 | $0.40 | $0.67 | ||
| Q2 25 | $0.27 | $0.07 | ||
| Q1 25 | $0.15 | $0.55 | ||
| Q4 24 | $0.14 | $0.46 | ||
| Q3 24 | $0.12 | $1.21 | ||
| Q2 24 | $0.29 | $0.23 | ||
| Q1 24 | $-0.24 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $618.7M |
| 总债务越低越好 | $153.8M | $9.0B |
| 股东权益账面价值 | $579.2M | $9.7B |
| 总资产 | $1.1B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.27× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资KERPRX
| Q4 25 | $77.9M | $618.7M | ||
| Q3 25 | $75.7M | $938.9M | ||
| Q2 25 | $88.8M | $631.9M | ||
| Q1 25 | $51.4M | $1.1B | ||
| Q4 24 | $53.9M | $929.0M | ||
| Q3 24 | $76.6M | $950.1M | ||
| Q2 24 | $78.0M | $1.8B | ||
| Q1 24 | $65.2M | $843.0M |
总债务KERPRX
| Q4 25 | $153.8M | $9.0B | ||
| Q3 25 | $137.5M | $8.9B | ||
| Q2 25 | $147.1M | $8.0B | ||
| Q1 25 | $178.3M | $7.6B | ||
| Q4 24 | $204.5M | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | $294.8M | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益KERPRX
| Q4 25 | $579.2M | $9.7B | ||
| Q3 25 | $577.1M | $9.6B | ||
| Q2 25 | $569.9M | $9.5B | ||
| Q1 25 | $548.1M | $9.8B | ||
| Q4 24 | $537.5M | $10.3B | ||
| Q3 24 | $547.8M | $10.3B | ||
| Q2 24 | $540.5M | $9.8B | ||
| Q1 24 | $539.1M | $9.9B |
总资产KERPRX
| Q4 25 | $1.1B | $19.6B | ||
| Q3 25 | $1.1B | $19.3B | ||
| Q2 25 | $1.1B | $18.3B | ||
| Q1 25 | $1.1B | $17.6B | ||
| Q4 24 | $1.1B | $18.2B | ||
| Q3 24 | $1.1B | $18.0B | ||
| Q2 24 | $1.2B | $17.7B | ||
| Q1 24 | $1.3B | $16.1B |
负债/权益比KERPRX
| Q4 25 | 0.27× | 0.92× | ||
| Q3 25 | 0.24× | 0.93× | ||
| Q2 25 | 0.26× | 0.84× | ||
| Q1 25 | 0.33× | 0.78× | ||
| Q4 24 | 0.38× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | 0.55× | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $6.9M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-11.2M | — |
| 自由现金流率自由现金流/营收 | -3.3% | — |
| 资本支出强度资本支出/营收 | 5.3% | — |
| 现金转化率经营现金流/净利润 | 1.89× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $81.8M | — |
8季度趋势，按日历期对齐
经营现金流KERPRX
| Q4 25 | $6.9M | $827.1M | ||
| Q3 25 | $8.1M | $702.6M | ||
| Q2 25 | $78.1M | $364.0M | ||
| Q1 25 | $30.9M | $596.1M | ||
| Q4 24 | $29.5M | $742.5M | ||
| Q3 24 | $45.5M | $703.6M | ||
| Q2 24 | $48.5M | $658.2M | ||
| Q1 24 | $42.6M | $664.6M |
自由现金流KERPRX
| Q4 25 | $-11.2M | — | ||
| Q3 25 | $-2.5M | — | ||
| Q2 25 | $68.4M | — | ||
| Q1 25 | $27.0M | — | ||
| Q4 24 | $23.1M | — | ||
| Q3 24 | $32.1M | — | ||
| Q2 24 | $39.5M | — | ||
| Q1 24 | $30.0M | — |
自由现金流率KERPRX
| Q4 25 | -3.3% | — | ||
| Q3 25 | -0.7% | — | ||
| Q2 25 | 18.0% | — | ||
| Q1 25 | 7.2% | — | ||
| Q4 24 | 6.5% | — | ||
| Q3 24 | 8.6% | — | ||
| Q2 24 | 9.2% | — | ||
| Q1 24 | 7.1% | — |
资本支出强度KERPRX
| Q4 25 | 5.3% | — | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | 1.8% | — | ||
| Q3 24 | 3.6% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | 3.0% | — |
现金转化率KERPRX
| Q4 25 | 1.89× | 3.86× | ||
| Q3 25 | 0.80× | 2.44× | ||
| Q2 25 | 11.86× | 12.06× | ||
| Q1 25 | 8.11× | 2.50× | ||
| Q4 24 | 8.58× | 3.57× | ||
| Q3 24 | 14.42× | 1.29× | ||
| Q2 24 | 6.43× | 6.45× | ||
| Q1 24 | — | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KE
| Automotive | $162.3M | 48% |
| Medical | $96.3M | 28% |
| Industrial | $82.7M | 24% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
